Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 491

1.

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.

Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O'Gorman C, Harrigan RH.

Clin Ther. 2010 Mar;32(3):472-91. doi: 10.1016/j.clinthera.2010.03.003.

PMID:
20399985
2.

Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.

Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano R, O'Gorman C, Harrigan RH.

Pharmacotherapy. 2010 Feb;30(2):127-35. doi: 10.1592/phco.30.2.127.

PMID:
20099987
3.

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN.

J Clin Psychopharmacol. 1998 Aug;18(4):296-304.

PMID:
9690695
4.
5.
6.
7.

Best clinical practice with ziprasidone IM: update after 2 years of experience.

Zimbroff DL, Allen MH, Battaglia J, Citrome L, Fishkind A, Francis A, Herr DL, Hughes D, Martel M, Preval H, Ross R.

CNS Spectr. 2005 Sep;10(9):1-15. Review.

PMID:
16247923
8.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
9.

Ziprasidone: first year experience in a hospital setting.

Centorrino F, MacLean E, Salvatore P, Kidwell JE, Fogarty KV, Berry JM, Baldessarini RJ.

J Psychiatr Pract. 2004 Nov;10(6):361-7.

PMID:
15583517
10.

The utility of intramuscular ziprasidone in the management of acute psychotic agitation.

Mendelowitz AJ.

Ann Clin Psychiatry. 2004 Jul-Sep;16(3):145-54.

PMID:
15517847
11.

A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.

Greco KE, Tune LE, Brown FW, Van Horn WA.

J Clin Psychiatry. 2005 Jul;66(7):928-9.

PMID:
16013910
12.

Ziprasidone: the fifth atypical antipsychotic.

Caley CF, Cooper CK.

Ann Pharmacother. 2002 May;36(5):839-51. Review.

PMID:
11978164
13.

Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.

Stimmel GL, Gutierrez MA, Lee V.

Clin Ther. 2002 Jan;24(1):21-37. Review.

PMID:
11833834
14.

The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy.

Daniel DG, Zimbroff DL, Swift RH, Harrigan EP.

Int Clin Psychopharmacol. 2004 Jan;19(1):9-15.

PMID:
15101564
15.
16.

Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia.

Barak Y, Mazeh D, Plopski I, Baruch Y.

Am J Geriatr Psychiatry. 2006 Jul;14(7):629-33.

PMID:
16816018
17.

Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.

Kudla D, Lambert M, Domin S, Kasper S, Naber D.

Eur Psychiatry. 2007 Apr;22(3):195-202. Epub 2006 Nov 29.

PMID:
17140769
18.

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.

Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP.

J Clin Psychiatry. 2001 Jan;62(1):12-8. Erratum in: J Clin Psychiatry 2001 Mar;62(3):209.

PMID:
11235922
19.

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

Greenberg WM, Citrome L.

CNS Drug Rev. 2007 Summer;13(2):137-77. Review.

20.

Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.

Gunasekara NS, Spencer CM, Keating GM.

CNS Drugs. 2002;16(9):645-52. Review.

PMID:
12153335
Items per page

Supplemental Content

Write to the Help Desk